Trinity Biotech plc has begun the commercial rollout of its upgraded Premier Hb9210 HbA1c column system in Brazil after receiving local regulatory approval on March 12 2026. The launch marks the company’s first entry into one of the world’s largest diabetes markets, where an estimated 16 to 18 million adults live with the disease.
The Premier Hb9210 platform is the only HbA1c system worldwide to receive the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) “Gold” classification for 2026, a designation that recognizes the highest levels of clinical accuracy, precision and traceability. The IFCC Gold status positions the system as a world‑leading solution for accurate HbA1c testing, especially in a market that demands reliable results.
"Brazil is one of the world’s most important diabetes markets, and regulatory approval of our upgraded Premier Hb9210 HbA1c system marks a significant step forward for our haemoglobin business and positions it well for long-term profitable growth," said John Gillard, President and CEO of Trinity Biotech. "With the Premier Hb9210 achieving IFCC Gold status for 2026 — the only system globally to do so — we are delivering world‑leading accuracy to a market that needs it most."
Despite the positive product launch, Trinity Biotech’s recent financial performance has been challenging. In Q2 2025 the company reported total revenue of $9.2 million, down 41.9 % year‑over‑year, and a net loss of $14.76 million. For Q4 2025, revenue is projected between $11.5 million and $12.5 million, compared with $15.9 million in Q4 2024. The company has also faced Nasdaq non‑compliance notices related to minimum market value and bid‑price requirements, raising delisting concerns.
The Brazil rollout is part of Trinity Biotech’s broader comprehensive transformation plan, which includes shifting to outsourced manufacturing and consolidating operations to improve profitability. The company is also developing other products, such as a continuous glucose monitoring device, a prostate cancer test, and a preeclampsia screening test, which could diversify revenue streams in the future.
Investors responded with a mixed reaction, weighing the product launch against ongoing financial challenges and regulatory compliance issues. The announcement highlights both a strategic milestone and the need for continued execution to achieve profitable growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.